The Prescription a Rock Climber's New HCM Diagnosis Doesn't Actually Need Yet
The real question isn't which drug to start. It's whether a diagnosis, on its own, without a single symptom attached to it, is a prescription at all.
T.N., a 33-year-old woman, competes in rock climbing at a regional level and trains six days a week, which is how her hypertrophic cardiomyopathy was found at all — an ECG obtained as part of a routine sports-cardiology screening before a competition, followed by an echocardiogram showing asymmetric septal hypertrophy consistent with HCM, non-obstructive, with a maximal wall thickness of 17 millimeters. She has no family history of HCM or sudden cardiac death that she's aware of, no chest pain, no exertional dyspnea, no palpitations, no syncope or presyncope, and a formal sudden-cardiac-death risk assessment — ambulatory monitoring, wall thickness, ejection fraction, family history — that turned up none of the features that would argue for a defibrillator — genuinely asymptomatic, found only because an incidental screening test looked for it in a population where nobody expected to find anything.
Her cardiologist raised starting a beta-blocker at the visit where her diagnosis was confirmed, and she is asking, reasonably, why she'd start a medication for a condition producing no symptoms she can identify. That question deserves a direct answer rather than a reflexive prescription: current HCM guidelines reserve pharmacologic therapy for symptomatic patients or those with outflow tract obstruction, neither of which applies to her, and no trial evidence supports starting a beta-blocker prophylactically in someone with confirmed but truly asymptomatic, non-obstructive disease. The ACE-inhibitor alternative some might consider carries its own separate caution in HCM generally, since reducing afterload and preload can worsen outflow tract obstruction in patients who have it — a mechanism less relevant to her specifically, since she has none, but part of why ACE inhibitors are not the reflexive second choice some clinicians reach for when avoiding a beta-blocker. Her situation is less a drug-selection question than a genuine question of whether medication of any kind is the right first move at all.
At the new-diagnosis cardiology consultation
I want to be direct with her: current guidelines reserve pharmacologic therapy for symptomatic HCM patients or those with outflow tract obstruction. She's neither. There's no trial evidence that starting a beta-blocker prophylactically in truly asymptomatic, non-obstructive disease changes her trajectory, and starting one would be treating a diagnosis rather than a symptom.
I'd raise the ACE-inhibitor question too, since it sometimes gets reached for as a gentler-seeming alternative when a beta-blocker feels like overtreatment. I want to name directly why that's not actually a safer default here: ACE inhibitors reduce afterload and preload, which can worsen outflow tract obstruction in HCM patients who have it. Not relevant to her specifically since she's non-obstructive, but worth stating clearly so it doesn't become someone else's reflexive substitute.
Agreed, and I think that's worth documenting even though it doesn't change her plan. No pharmacologic therapy started. Continued athletic participation at her current level, per current guidance, which has moved away from blanket disqualification and supports participation after comprehensive evaluation and shared decision-making with a specialist rather than treating the diagnosis itself as disqualifying, with structured periodic re-evaluation and a clear personal plan for what new symptoms should prompt an earlier visit rather than waiting for the next scheduled one.
No pharmacologic therapy started. Continued athletic participation at her current competitive level affirmed. Structured periodic clinical and echocardiographic reassessment scheduled, with a clear personal action plan for new symptoms.
Agreed without real disagreement on her specific plan; the broader point both physicians wanted documented:
A confirmed HCM diagnosis, on its own, is not automatically a prescription — the decision to treat should track symptoms and outflow obstruction, not the existence of the diagnosis itself, and this applies whether the medication being considered is a beta-blocker or an ACE inhibitor.